Ignite Creation Date:
2025-12-24 @ 1:39 PM
Ignite Modification Date:
2026-01-14 @ 5:18 PM
Study NCT ID:
NCT02753595
Status:
TERMINATED
Last Update Posted:
2020-07-13
First Post:
2016-04-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-07-13
Start Date Type:
ACTUAL
Primary Completion Date:
2019-08-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-08-16
Completion Date Type:
ACTUAL
First Submit Date:
2016-04-26
First Submit QC Date:
None
Study First Post Date:
2016-04-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-06-25
Results First Submit QC Date:
None
Results First Post Date:
2020-07-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-06-25
Last Update Post Date:
2020-07-13
Last Update Post Date Type:
ACTUAL